SCHEMBL23590235

SCHEMBL23590235

CCNc1cccc(-c2ccc(-c3cc(C(=O)O)c4cc(C(F)(F)F)ccc4n3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 6/20 0.51
▸ HSD17B10 Q99714 4/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ TP53 P04637 2/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ HIF1A Q16665 2/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ KMT2A Q03164 1/20 0.46
▸ PDE10A Q9Y233 1/20 0.46
▸ PTGES O14684 1/20 0.46
▸ ALOX5 P09917 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CASP7 P55210 1/20 0.46
▸ CDK2 P24941 3/20 0.45
▸ LMNA P02545 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ XBP1 P17861 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23590237 0.92 HSD17B10 (0.51) DHODHHSD17B10ALDH1A1TP53CYP1A2
SCHEMBL23590041 0.90 DHODH (0.44) DHODHHSD17B10ALDH1A1KDM4ECDK2
SCHEMBL23590264 0.89 DHODH (0.46) DHODHHSD17B10ALDH1A1TP53CYP1A2
SCHEMBL23590255 0.87 DHODH (0.69) DHODHHSD17B10ALDH1A1TP53CYP1A2
SCHEMBL26075605 0.86 ACP1 (0.42) DHODHALDH1A1TP53HPGDLMNA
SCHEMBL23590329 0.82 KDM4E (0.58) DHODHHSD17B10ALDH1A1TP53CYP1A2
SCHEMBL23590232 0.82 DHODH (0.51) DHODHHSD17B10ALDH1A1TP53CYP1A2
SCHEMBL23590038 0.82 DHODH (0.45) DHODHHSD17B10ALDH1A1TP53CYP1A2
SCHEMBL23590308 0.82 DHODH (0.68) DHODHHSD17B10ALDH1A1TP53CYP1A2
SCHEMBL23590231 0.82 HSD17B10 (0.54) DHODHHSD17B10ALDH1A1TP53CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase OHIO STATE INNOVATION FOUNDATION (US) 2022-04-26 — — US disclosed
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE HENDRIX COLLEGE 2022-03-03 — — US disclosed
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION 2021-08-19 — — US disclosed
WO-2021134045-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase DHODH, DLD, DPYD DHODH 1/4885HSD17B10 165/4885ALDH1A1 72/4885
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD DHODH 1/4885HSD17B10 130/4885ALDH1A1 88/4885
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD DHODH 1/4885HSD17B10 172/4885ALDH1A1 64/4885
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD DHODH 1/4885HSD17B10 165/4885ALDH1A1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback